Amgen Inc.

(NASDAQ Global Select)
Back to all articles
Neutral +10

Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?

Earnings report Financial outlook Guidance raised AI-generated analysis

📉 AMGN faces a profit squeeze with Q3 consensus EPS of $5.79 expected to be below Q2's $6.29 despite strong prior quarter performance.

💰 Outgoing CFO Peter Griffith warned of a meaningful sequential increase in operating expenses, including a $100 million upfront R&D charge.

📉 Legacy drug erosion is severe with Prolia down 32% and XGEVA down 34% due to biosimilar competition pressures.

💊 Growth reliance on Repatha (+37%), EVENITY (+38%), and TEZSPIRE (+42%) must offset declining legacy revenue streams.

🔬 The company is funding nine global Phase III MariTide trials with capital expenditures guided at approximately $2.6 billion.

📉 Operating margins are under pressure, having slipped 0.5 percentage points in Q2 and guiding to a lower full-year range of 45-46%.

💸 Amgen carries $57.3 billion in debt with no buybacks executed in the first two quarters of the year.

📈 The stock has rallied 41.28% year-to-date, but investors are questioning if revenue momentum can cover higher costs.

👔 Management transition is underway as Thomas Dittrich prepares to succeed Peter Griffith as CFO ahead of earnings.

📅 Full-year revenue guidance was raised to $38.2 billion to $39.4 billion, though EPS guidance was lowered to $22.30-$23.50.

Bullish Signals
  • Amgen posted a fifth consecutive EPS beat last quarter with non-GAAP EPS of $6.29 against a consensus of $5.62.
  • Revenue reached $10.05 billion in the prior quarter, up 9.7% year over year and ahead of analyst estimates.
  • Growth brands Repatha, EVENITY, and TEZSPIRE are showing strong momentum with sales increases of 37%, 38%, and 42% respectively.
  • The company raised its full-year revenue guidance to a range of $38.2 billion to $39.4 billion following the previous quarter's results.
  • New product IMDELLTRA saw sales surge 115% as it expands into Europe and China markets.
Risk Factors
  • Q3 consensus EPS of $5.79 is significantly below Q2's $6.29, indicating expected profit deceleration.
  • Outgoing CFO Peter Griffith warned of a meaningful sequential increase in operating expenses for the third quarter.
  • Legacy products are eroding rapidly with Prolia falling 32% and XGEVA dropping 34% due to biosimilar competition.
  • Operating margins slipped 0.5 percentage points in Q2, and full-year guidance is lowered to a range of 45-46% from 48%.
  • The company faces a $100 million upfront payment tied to a business-development deal booked to R&D expenses.
  • Nine ongoing global Phase III MariTide trials are burning through cash with capex guided at approximately $2.6 billion.
  • Amgen carries a high debt load of $57.3 billion with no buybacks executed in the first two quarters of the year.
Full Analysis
Amgen (AMGN) is preparing to report its third-quarter earnings on November 3, facing a potential profit squeeze driven by rising operating expenses and legacy drug erosion. The company posted a fifth consecutive EPS beat in the prior quarter with revenue of $10.05 billion, but analysts now expect Q3 non-GAAP EPS of $5.79, down from $6.29 in Q2, as management warns of a meaningful sequential increase in costs. Outgoing CFO Peter Griffith highlighted a specific $100 million R&D charge related to a business-development deal and noted that the operating margin has already slipped 0.5 percentage points in Q2. The company's full-year non-GAAP guidance for margins stands at 45% to 46%, lower than the 48% achieved in Q2, signaling pressure on profitability as it invests heavily in its pipeline. Revenue growth will rely heavily on blockbuster brands Repatha, EVENITY, and TEZSPIRE to offset significant declines in legacy products like Prolia, which fell 32%, and XGEVA, which dropped 34% due to biosimilar competition. Additionally, the company is burning cash on nine ongoing global Phase III MariTide trials with capital expenditures guided at approximately $2.6 billion for the year. Investors are closely watching whether Amgen can maintain its raised full-year revenue guidance of $38.2 billion to $39.4 billion while managing high debt levels of $57.3 billion and a transition to new CFO Thomas Dittrich. The stock has gained nearly 42% year-to-date, but the market will determine if the company's investment strategy in late-stage programs can sustain its growth trajectory without further margin contraction.